PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
NCT05430698
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
62
Enrollment
OTHER
Sponsor class
Conditions
Perihilar Cholangiocarcinoma
Interventions
DRUG:
PD-1antibody plus GEMOX
Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University